A leading manufacturer of automated insulin delivery systems, Dexcom (NASDAQ: DXCM) signed a five-year collaboration agreement with the University of Virginia on Thursday . The company will fund research at the university that could expand its addressable patient population.
Dexcom already has clinical trial evidence that shows its constant glucose monitoring (CGM) technology reduces the amount of time Type 1 diabetes patients spend with blood sugar levels that are too high or too low. Through its collaboration with the university, the company will test its CGM technology for use among people with Type 2 and gestational diabetes, as well as for hospitalized patients.
Image source: Getty Images.
For further details see:
Dexcom and University of Virginia to Advance Diabetes Research Together